This newly developed technology is the first of its kind where Circulating Tumor Cells (CTC) are isolated and treated with Immunochemistry, DNA FISH, mRNA FISH, and PCR chemistries on the manual JETTA100 instrument. The JETTA100 is the precursor system to the Company’s fully automated JETTA400, to be released mid-year 2014. In addition to instrumentation, the Company has developed both general and specific reagents for Breast, Prostate and Colorectal Cancers for use in the Research Market.
“With the commercial introduction of our JETTA100 System and line of consumables at AACR, DeNovo will be able to take advantage of the remaining nine months of 2014 to generate positive revenues”, says Mark Powelson, the Company’s Chief Commercial Officer. “Even though our products are only focused in the Research Market today, we will begin preparing to take our full line of products through the FDA process later this year.” Powelson went on to say, “This year’s AACR Conference delivered the perfect audience for us to introduce our first product and we are looking forward to release our automated systems at the American Society of Clinical Oncology Conference in June this year.”
One of the keys to monitoring metastatic disease is to understand how these rare cells migrate to other tissue or organs. With the ability to recover the bulk of these cells from a liquid or small tissue sample, it will provide researchers the ability to better monitor CTC activity and migration patterns.
CTCs have been shown in many studies to be possible biomarkers for metastasis and may be instrumental for the spread of the disease. Key to monitoring metastatic disease is the understanding of how these rare cells migrate to other parts of a patient’s body. The ability to recover high percentages of these cells enable researchers to better track CTC activity and monitor the effectiveness of a specific cancer treatment.
For more information, visit DeNovo Sciences.